LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate
LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.
How this was made
The 30-second read
Why it matters
The quarter combined a revenue/EPS miss with a larger-than-expected reduction in full-year 2026 revenue and adjusted EBITDA range, prompting a sharp after-hours decline.
Market read
Traders are likely to focus on the guidance cut and the path to adjusted EBITDA breakeven, not just gross margin and subscriber growth.
What to watch
The article notes the transition away from compounded GLP-1s is near completion (95% of new Weight Management patients on branded GLP-1s), which may improve longer-term unit economics despite the near-term guidance reset.
Background
LifeMD is shifting its revenue mix toward recurring subscriptions and branded GLP-1 therapies, with an in-house pharmacy and telehealth plus affiliated medical group.
Ticker impact
LifeMD reported Q2 2026 revenue of $47.3M and GAAP EPS loss of $0.16, missing consensus and cutting full-year 2026 guidance.
Bearish near-term bias; elevated volatility likely as traders digest the guidance reset and subscriber mix shift to branded GLP-1s.
The article cites both the miss (revenue and EPS) and a material guidance reduction for 2026, alongside a 12.23% after-hours drop.
Market effects
Signals pressure on virtual-care profitability and the earnings sensitivity of GLP-1 transition economics for subscription-based telehealth models.
Primarily impacts US small-cap healthcare/telehealth sentiment; limited direct cross-region spillover implied.
Low global relevance beyond the US virtual-care and GLP-1-adjacent investor cohort.
Counterpoint
Gross margin expanded to ~89% and subscribers rose to ~356,000, suggesting operating leverage could re-emerge if acquisition spending normalizes.
Key entities
- companyLifeMD, Inc.
Nasdaq-listed virtual-care provider reporting Q2 2026 results and reduced 2026 guidance.
- executiveJustin Schreiber
Chairman and CEO quoted on longer patient relationships and diversified acquisition model.
- executiveAtul Kavthekar
CFO quoted on gross margin expansion drivers and pharmacy scaling.
